Neon Therapeutics Enters License Agreement with Broad Institute, Dana-Farber and Mass General

Download IconDownload Print IconPrint

Neon Therapeutics Enters License Agreement with Broad Institute, Dana-Farber and Mass General

Firm News

Related Solutions

Providing comprehensive solutions for the acquisition, enforcement and protection of IP.
A global team handling highly complex and sensitive matters in all aspects of litigation.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.
We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On December 9, 2015, Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, announced that the company has entered into a license agreement with the Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital for technology to be utilized in Neon Therapeutics' pipeline.

Neon Therapeutics was represented by WilmerHale in this transaction, with Partners Richard Hoffman and Michael Bevilacqua, and Associate Ritu Gupta.

View Neon Therapeutics' press release for more information.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel